Close Menu

Anti-RA 33: A Marker of Good Prognosis in Seronegative Rheumatoid Arthritis



Objective: Autoantibodies are evident in the early stages of rheumatoid arthritis (RA) and play important roles in diagnosis. The aim of this study was to investigate the diagnosis capability and extent of Anti-RA 33 positivity and clinical characteristics in patients with RA.

Methods: We included 67 RA patients and 20 healthy subjects in our study. Duration of symptoms, duration of disease, the extent of delay in diagnosis, epiosodes of clinical remission, type and number of disease-modifying antirheumatic drugs (DMARDs) taken were noted.  To evaluate quality of life, the Health Assessment Questionnaire (HAQ) disability index (consisting of 20 questions) was applied. Disease activity was evaluated with Disease activity score (DAS)28. The laboratory assessments included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and serologic assessments for RF, anti-CCP and anti-RA 33.

Results: The mean disease duration was 14.56 months. A total of 38 (56.7%) patients were positive for Anti-RA 33 antibodies. Twenty-four (63%) of patients positive for Anti-RA 33 were clinically in remission. A negative correlation was evident between Anti-RA 33 positivity and number of DMARDs taken, HAQ score (r=-0,766, p<0.001; r= -0.737, p<0.001). A positive correlation was evident between Anti-RA 33 positivity and DAS 28 score (r=0.287, p=0.019)

Conclusion: Anti-RA 33 antibodies have poor diagnostic capability in patients with RA. Anti-RA 33 antibodies may exert helpful effects determining prognosis in established RA patients.

22 Aug, 2016
PDF Attachment: 
e-Published: 07 Sep, 2016


Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.

Top of Page